Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
Recruiting · NCT07231445 · Interventional (participants receive a specific treatment) · Lead sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This is a randomized, multicenter, phase Ib study to evaluate the safety and efficacy of ZG006 combined with PD-1/PD-L1 immune checkpoint inhibitors (±chemotherapy) as first-line therapy in Participants with extensive stage small cell lung cancer.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Participants with histologically or cytologically confirmed ES-SCLC.
- Fully understand the study and voluntarily sign the informed consent form;
- Male or female 18\~75 years of age;
- Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1;
- Life expectancy ≥ 3 months;
Exclusion criteria
- Participants were deemed unsuitable for participating in the study by the investigator for any reason.
Where it is running
1 location listed.
- Shanghai Chest Hospital - Shanghai, Shanghai Municipality, China